Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis

Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial

(2009) Asher Chanan-Khan et al.   LEUKEMIA & LYMPHOMA

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

(2008) A. Ferrajoli et al.   BLOOD

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Lenalidomide for the Treatment of B-Cell Malignancies

(2008) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide-Associated Tumor Flare Reaction Is Manageable in Patients With Chronic Lymphocytic Leukemia

(2008) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE